Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Anxiolytic Drugs: Overview

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of neutrophil percentage-to-albumin ratio with sepsis in infant.

Annals of medicine·2026

Same author

Unmixing the Neck: Accurate Jugular Venous Pulse Detection From Wearable PPG.

IEEE journal of biomedical and health informatics·2026

Same author

High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study.

Annals of medicine·2026

Same author

Longitudinal association between sarcopenia and comorbidity of mild cognitive impairment and depression among older adults in China: the moderating effect of non-obesity.

BMC geriatrics·2026

Same author

Bibliometric analysis and data visualization on drug delivery systems for infectious keratitis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Same author

Increasing salinity exacerbates the bioaccumulation and toxicity of perfluorooctanoic acid (PFOA) in Manila clams (Ruditapes philippinarum).

Marine pollution bulletin·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

Ocular Adverse Events Associated With Antidepressants: A Large-Scale Data Analysis From the FAERS Database.

Yiming Peng¹, Yichen Cao¹, Hanhan Liu²

¹Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

CNS Neuroscience & Therapeutics

|June 17, 2026

Summary

Antidepressant use is linked to eye problems, especially with Norepinephrine-dopamine reuptake inhibitors (NDDIs) and Selective serotonin reuptake inhibitors (SSRIs). These drugs can cause neuromuscular eye disorders, requiring careful monitoring.

Keywords:

FAERS NDDIs SSRIs antidepressants ocular adverse events pharmacovigilance

Related Experiment Videos

Last Updated: Jun 18, 2026

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

Area of Science:

Pharmacovigilance
Ophthalmology
Psychiatry

Background:

Global antidepressant use has increased significantly.
Concerns exist regarding potential ocular adverse effects of antidepressants.
Comprehensive large-scale assessments of these ocular side effects are limited.

Purpose of the Study:

To conduct a comprehensive assessment of ocular side effects associated with various antidepressant classes.
To identify specific antidepressant classes and drugs linked to ocular adverse events.
To investigate the association between antidepressants and ocular neuromuscular disorders.

Main Methods:

Retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) from Q1 2015 to Q4 2024.
Systematic extraction of antidepressant-associated reports.
Disproportionality analyses to identify associations with ocular adverse events (AEs).

Main Results:

62,020 ocular AE reports were identified in 13,348 patients.
Norepinephrine-dopamine disinhibitors (NDDIs) showed the strongest association with eye disorders (IC 3.84).
Selective serotonin reuptake inhibitors (SSRIs) had the most positive associations with ocular AEs. 33 of 36 antidepressants analyzed were linked to ocular neuromuscular disorders like mydriasis and miosis.

Conclusions:

This study highlights the ocular risks associated with antidepressants, particularly NDDIs and SSRIs.
A widespread association exists between antidepressants and ocular neuromuscular disorders.
Vigilant monitoring and early intervention are crucial for the safe clinical use of antidepressants.